Header

UZH-Logo

Maintenance Infos

Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells


Generali, Melanie; Kehl, Debora; Wanner, Debora; Okoniewski, Michal J; Hoerstrup, Simon P; Cinelli, Paolo (2022). Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. Journal of Cellular and Molecular Medicine, 26(1):228-234.

Abstract

The outbreak of COVID-19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID-19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS-CoV-2 entry has been detected in all MSC samples. These results are of particular importance for future MSC-based cell therapies to treat severe cases after COVID-19 infection.

Keywords: adult stem cells; cellular therapy; mesenchymal stromal cells (MSCs); sars-CoV-2

Abstract

The outbreak of COVID-19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID-19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS-CoV-2 entry has been detected in all MSC samples. These results are of particular importance for future MSC-based cell therapies to treat severe cases after COVID-19 infection.

Keywords: adult stem cells; cellular therapy; mesenchymal stromal cells (MSCs); sars-CoV-2

Statistics

Citations

Dimensions.ai Metrics
2 citations in Web of Science®
3 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

19 downloads since deposited on 03 Dec 2021
7 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Department of Trauma Surgery
04 Faculty of Medicine > Institute for Regenerative Medicine (IREM)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 January 2022
Deposited On:03 Dec 2021 10:24
Last Modified:16 Jun 2024 03:41
Publisher:Wiley Open Access
ISSN:1582-1838
OA Status:Gold
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1111/jcmm.17048
PubMed ID:34821008
  • Content: Published Version
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)